Clinical Trials Logo

Clinical Trial Summary

The main goal of this clinical study is to evaluate the safety of the Qidni/D Hemodialysis System in patients with end-stage renal disease. The main question it aims to answer is: Is the Qidni/D safe for performing hemodialysis? Participants will be subjected to one treatment of hemodialysis for up to 4 hours with the use of the Qidni/D.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06086470
Study type Interventional
Source Qidni Labs Inc.
Contact Morteza Ahmadi, PhD
Phone 2266060956
Email ma@qidni.com
Status Recruiting
Phase N/A
Start date May 1, 2023
Completion date July 14, 2024

See also
  Status Clinical Trial Phase
Withdrawn NCT04665310 - Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant Phase 4
Completed NCT02964429 - Determination In-vivo KUF for Diacap Pro Hemodialyser N/A
Recruiting NCT04634916 - Post-market Surveillance Study of the BD® WavelinQâ„¢ EndoAVF System N/A
Not yet recruiting NCT06089473 - Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates N/A
Completed NCT03149328 - Electronic Patient-Reported Outcomes in Clinical Kidney Practice (ePRO Kidney) N/A
Active, not recruiting NCT04484220 - Ellipsys Vascular Access System Post Market Surveillance (PS) Study N/A